After going on this medicine, "The first thing I noticed was, 'I don't think about food anymore,'" she says
We have to look at patients holistically, who have kidney disease and diabetes, to address the totality of risks, certainly progression to kidney failure, but also prevention of cardiovascular events and deaths. Ozempic and other GLP-1s will be compared to another diabetes drug class, SGLT-2 inhibitors Given Ozempics reduction of kidney disease events in the FLOW study, it seems likely that the GLP-1s will be used together with and compared against SGLT-2 inhibitor drugs
Claims graded by evidence type
10.1080/21678421.2023.2245858 129 MerryT
How to Speak to a UK Doctor About Emerging Weight Loss Options Your GP is the appropriate first point of contact to discuss weight management options, assess eligibility for approved treatments, and advise on UK clinical trial access via the NIHR 'Be Part of Research' portal